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Sheep scrapie is the prototypical transmissible spongiform encephalopathy (prion disease), which has a
fundamental pathogenesis involving conversion of normal cellular prion protein (PrPC [C superscript stands
for cellular]) to disease-associated prion protein (PrPSc [Sc superscript stands for sheep scrapie]). Sheep
microglial cell cultures, derived from a prnp 136VV/171QQ near-term fetal brain, were developed to study sheep
scrapie in the natural host and to investigate potential cofactors in the prion conversion process. Two culture
systems, a primary cell culture and a cell line transformed with the large T antigen of simian virus 40, were
developed, and both were identified as microglial in origin as indicated by expression of several microglial
phenotype markers. Following exposure to PrPSc, sheep microglial cells demonstrated relatively low levels
(transformed cell line) to high levels (primary cell line) of PrPSc accumulation over time. The accumulated
PrPSc demonstrated protease resistance, an inferred beta-sheet conformation (as determined by a commercial
enzyme-linked immunosorbent assay), specific inhibition by anti-PrP antibodies, and was transmissible in a
dose-dependent manner. Primary microglia coinfected with a small-ruminant lentivirus (caprine arthritis
encephalitis virus-Cork strain) and PrPSc demonstrated an approximately twofold increase in PrPSc accumu-
lation compared to that of primary microglia infected with PrPSc alone. The results demonstrate the in vitro
utility of PrPSc-permissive sheep microglial cells in investigating the biology of natural prion diseases and show
that small-ruminant lentiviruses enhance prion conversion in cultured sheep microglia.
Prion diseases (transmissible spongiform encephalopathies
[TSEs]) are a group of invariably fatal, transmissible, neuro-
degenerative diseases, which include scrapie in sheep and
goats, bovine spongiform encephalopathy in cattle, chronic
wasting disease in deer and elk, and Creutzfeld-Jakob disease
and kuru in humans (38). The similarities between scrapie and
Creutzfeld-Jakob disease have long been recognized (36), and
the use of scrapie as an experimental model allows for the
investigation of a natural prion disease in a natural host. The
central feature of prion pathogenesis is the conversion of
the normal cellular form of the host-encoded prion protein
(PrPC [C superscript stands for cellular]) to an abnormal iso-
form, designated PrPSc (Sc superscript stands for sheep
scrapie) (6, 10, 13). The conversion occurs posttranslationally
and involves a conformational change resulting in the genera-
tion of a detergent-insoluble, partially protease-resistant mol-
ecule that aggregates in affected tissues and serves as the
marker for prion diseases. The principal component of the
transmissible agent is thought to be the abnormal prion protein
and provides the basis for the protein-only hypothesis of prion
diseases (50).
There are at least 21 cell lines that have been used to study
prion diseases in vitro (59). However, only 4 of these are
susceptible to PrPSc derived from a natural TSE host, while the
remaining 17 cell lines are susceptible only to rodent-adapted
strains of PrPSc. Further, only one of the cell lines is derived
from a natural TSE host, mule deer (Odocoileus hemionus)
(51). While rodent-derived cells have many benefits, including
the availability of reagents and highly inbred genetics, much of
the work accomplished in these cells has to be verified in a
natural host-TSE system. The lack of a sheep-derived, scrapie-
permissive cell line also prevents full investigation into species-
specific phenomena, such as allelic usage variation, allele-pre-
dicted susceptibility, and species-specific cofactors. Therefore,
the development of a sheep cell culture system would provide
an excellent model for such studies.
In addition to creating cell lines that accumulate PrPSc, it is
also desirable to use cells that contribute to the pathophysiol-
ogy of the clinical disease. Microglia (resident brain macro-
phages) are such cells, which not only accumulate infectivity in
vivo (5) but are also thought to play a role in the neuropathol-
ogy by their activation and release of immune mediators, such
as interleukin-6 (8, 52, 63). Additionally, peripheral macro-
phages have demonstrated both accumulation (9, 23, 28, 41,
49) and proteolysis of PrPSc (9, 28). Only one of the current
cell culture systems demonstrates microglial or macrophage
characteristics, and this cell line is derived from mice and
overexpresses the murine prion gene (33). While overexpres-
sion of PrPC often increases the permissiveness of cells to
PrPSc accumulation, it can also introduce spontaneous cell
pathology (62) and is a confounding factor when trying to study
the effects of PrPSc accumulation at the cellular level.
Another area that would benefit from a natural host-TSE
cell culture system is the investigation into possible cofactors
for the prion conversion process (55). Identification of these
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accessory molecules is still unresolved; however, several stud-
ies suggest that nucleic acids are a possible family of cofactors
(2, 14, 15, 18, 19, 21, 64). Interestingly, recombinant prion
protein has demonstrated the abilities to bind and to chaper-
one retroviral RNA, which are similar to retroviral nucleocap-
sid’s function (18, 19, 42). Other interactions between prion
protein and retroviruses have been identified; these interac-
tions include an increase in murine leukemia virus (MLV)
titers and replication and a shortened scrapie incubation pe-
riod in the brains of coinfected mice (12, 40). In vitro coinfec-
tion studies have also demonstrated increased scrapie infectiv-
ity release into the cell culture supernatant in murine cell
cultures coinfected with MLV (39).
Sheep, the natural host of scrapie, are also clinically affected
by retroviruses, most notably the small-ruminant lentiviruses
(SRLVs), visna-maedi virus (VISNA), and caprine arthritis-
encephalitis virus (CAEV) (47). These viruses have a world-
wide distribution and are the target of eradication programs
(47). However, there has been little work published regarding
any possible correlation between scrapie and infection with
SRLV, with only one report to the authors’ knowledge dem-
onstrating a correlation between VISNA-induced lymphofol-
licular mastitis and resulting PrPSc accumulation within mac-
rophages and follicular dendritic cells (41). Other studies have
demonstrated that chronic inflammation of various organs re-
sults in PrPSc accumulation within those organs that normally
lack PrPSc in prion-affected animals (26, 37), suggesting that
the effect of VISNA on PrPSc in mastitis was indirect. To
directly determine whether coinfection with an SRLV in-
creases accumulation of PrPSc, a sheep microglial cell culture
system was developed and utilized in coinfection studies with
PrPSc and SRLV.
MATERIALS AND METHODS
Primary ovine brain cell cultures. Primary mixed glial cell cultures were
obtained from an ovine fetal brain using a mechanical dissociation technique for
small ruminants previously described in our laboratory (7). The ovine fetus was
obtained from a near-term pregnant Suffolk cross ewe that was housed and cared
for in accordance with the guidelines of the Institutional Animal Care and Use
Committee at Washington State University, Pullman. At approximately day 102
of gestation, the ewe was euthanized by administering an intravenous overdose
of barbiturate, and the fetal brain was removed in toto. Approximately 250 mg of
brain tissue was removed from the cerebral cortex and used for genotyping of the
fetal prion gene as previously described (3). Periventricular white matter tissue
from the remainder of the cerebral cortices and midbrain was collected, cut into
approximately 5-mm cubes, and disassociated by mechanical triturating in a
25-ml pipette. The resulting brain tissue explants were plated into 75-cm2 tissue
culture flasks with Dulbecco’s modified Eagle’s medium (Cellgro) supplemented
with 20% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM
sodium pyruvate, 10 IU/ml of penicillin, 10 mg/ml streptomycin, and 2.5 g/ml
amphotericin B and left undisturbed for approximately 1 week. Once the cells
reached confluence, aliquots of cells were frozen in 90% heat-inactivated FBS
and 10% dimethyl sulfoxide and stored in liquid nitrogen. Aliquots of cells were
thawed as needed and serially passaged, using standard techniques, in OPTI-
MEM I reduced serum medium (Invitrogen) supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 10 IU/ml of penicillin, and 10 mg/ml of
streptomycin (OMEM).
Transformation of brain cells. Cells were transfected according to the man-
ufacturer’s instructions using the LF2000 reagent (Invitrogen), with a plasmid
containing the simian virus 40 (SV40) large T antigen, as described previously
(25, 27). Primary cells were split in triplicate into 24-well plates and allowed to
grow to approximately 60% confluence. Three wells of cells were incubated with
plasmid DNA in LF2000 reagent (Invitrogen) and OPTI-MEM for 8 hours at
37°C in 5% CO2, while the three remaining wells were sham transfected by
incubating in LF2000 reagent and OPTI-MEM without plasmid DNA. Following
8 hours, the cell culture medium was changed to OMEM. Cells were fed every 4
days and allowed to grow for 12 days. Cells were then lifted from the plate and
passed without dilution into 25-cm2 plastic tissue culture flasks. Cells were fed
every 3 to 5 days as needed and serially passaged 1/10 after reaching confluence.
Transfected cells demonstrated an increase in mitotic activity and a loss of
contact inhibition. Immunocytochemistry, with the SV40 large-T-antigen-specific
monoclonal antibody (MAb) DP02A (Oncogene Research Products, Cambridge,
MA), was used to confirm transfection as previously described (27).
Characterization of microglial cell cultures. To characterize brain cell cul-
tures, the brain cell cultures were phenotyped using various cell markers and
functional activity assays. The microglial and endothelial marker biotinylated
Ricinus communis agglutinin-1 (RCA-1) (Dako Cytomation) was used in immu-
nocytochemistry and flow cytometry as previously described (7). Nonspecific
esterase activity (Sigma) was performed per the manufacturer’s directions (7).
Two additional markers, CD14 (catalog no. MM61A; VMRD, Inc.) (immuno-
globulin G1 [IgG1]) and CD68 (EBM11; Dako) (IgG1), that are predominately
found on cells of the monocytic lineage were tested by immunocytochemistry and
flow cytometry. In cells of the monocyte lineage, CD14 is a membrane-bound
receptor for lipopolysaccharide (34). CD68 is a lysosome-associated glycoprotein
used to identify macrophages (30), and while the MAb EBM11 was raised against
human CD68, it has previously demonstrated immunoreactivity against bovine
macrophages (1), thus suggesting its utility in this study of sheep cells. For flow
cytometric detection of CD14 expression, cells were trypsinized and incubated
with the primary antibody. Following three washes, cells were incubated with a
secondary fluorescein isothiocyanate-conjugated goat anti-mouse immunoglob-
ulin antibody. Cells were then washed twice and fixed in 2% formaldehyde. CD68
is a predominately intracellular antigen; therefore, cells were fixed for 2 days in
10% neutral buffered formalin, permeabilized in 0.1% Triton X-100 in phos-
phate-buffered saline (PBS) for 5 min, washed, and then labeled as described
above. Five thousand events were analyzed on a FACSort flow cytometer (Bec-
ton Dickinson), and counts were determined with Macintosh CellQuest software
(BD Biosciences). Results were graphically analyzed using FCS Express (De
Novo Software). The Kolmogorov Smirnov test (CellQuest), with a cutoff P value
of 0.05, was used to determine significance. Negative controls included the use of
isotype-matched antibodies raised against an irrelevant antigen, omission of the
primary antibody, and omission of both the primary and secondary antibodies.
For immunocytochemistry, cells were grown in chambered glass slides (Nunc)
and allowed to grow to approximately 70% confluence. Cells were rinsed in PBS
and fixed in 100% ethanol for 10 minutes. Following quenching of endogenous
peroxidase with hydrogen peroxide for 10 min, cells were assayed for expression
of the antigens, using the Signet kit (Covance) per the manufacturer’s instruc-
tions, and the antibodies listed above. The immunolabeling was visualized with
3-amino-9-ethylcarbazole (Dako) with nuclear counterstaining by Mayer’s he-
matoxylin. Negative controls included the use of isotype-matched antibodies
raised against an irrelevant antigen, omission of the primary antibody, and
omission of both the primary and secondary antibodies.
Inoculation of primary microglia with PrPSc. Rov9 cells, which are rabbit renal
epithelial cells that are stably transfected with the sheep VRQ (Val-136, Arg-154,
and Gln-171) allele of the prion gene under the control of a tetracycline-induc-
ible promoter and are susceptible to sheep PrPSc (60), were used as the inocu-
lum. Rov9 cells with detectable amounts of PrPSc (Rov9Sc) and Rov9 cells that
were never exposed to PrPSc (Rov9C) were obtained (B. Caughey with permis-
sion from D. Vilette) and maintained in OMEM supplemented with 1 g/ml
doxycycline) as previously described (60). PrPSc within Rov9Sc cells was verified
by PrPSc-specific immunoblotting and enzyme-linked immunosorbent assay
(ELISA) (see below). For use as an inoculum, mechanical lysates of the Rov9Sc
and Rov9C cells were prepared as previously described (60). Briefly, the Rov9
cells were grown to confluence in two 75-cm2 plastic tissue culture flasks. Rov9Sc
and Rov9C cells were rinsed three times with sterile 1 Dulbecco’s phosphate-
buffered saline (D-PBS) and scraped into 10 ml of PBS. The cell pellets were
collected by centrifugation at 170  g at room temperature for 10 min and
resuspended in 0.5 ml of filter-sterilized 5% glucose. The cell suspensions were
frozen and thawed four times and then subjected to 1 to 2 min of sonication in
a cup horn sonicator. The inoculum was stored at 20°C. For inoculation,
primary microglia were passed into six-well plates and allowed to grow to ap-
proximately 60% confluence. Microglia were rinsed once with PBS and then
overlaid with 200 l of a 1/20 dilution of either the Rov9Sc lysate (microgliaSc) or
the Rov9C lysate (microgliaC) in OPTI-MEM. MicrogliaSc and microgliaC were
incubated for 6 hours, and then 200 l of OMEM was added to each well.
Following an additional 2 days of incubation, an additional 0.5 ml of OMEM
was added to each well, and microglia were incubated for 4 days at which time
they were expanded into 25-cm2 tissue culture flasks. Microglia were fed
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every 3 or 4 days with OMEM as necessary and serially passaged 1/5 after
reaching confluence.
Detection of PrPSc by ELISA. At selected passages following trypsinization,
four-fifths of the microglial cell suspension from a 25-cm2 tissue culture flask was
rinsed in D-PBS and then lysed in 120 l of lysis buffer (0.5% Triton X-100, 0.5%
sodium deoxycholate, 50 mM Tris-HCl [pH 8.0], 5 mM EDTA, and 150 mM
NaCl) for 3 min at room temperature, followed by centrifugation at approxi-
mately 2,300  g at room temperature for 5 min. One hundred microliters of the
supernatant was then used for PrPSc detection by the HerdChek scrapie antigen
test kit ELISA (IDEXX) following the manufacturer’s instructions. The propri-
etary ELISA positive and negative controls were used per the manufacturer’s
directions.  standard curve prepared from diluted Rov9Sc inoculum (1/20,
1/100, and 1/400) was used to normalize corrected optical density results. Mi-
crogliaSc results for cells two passages after inoculation with PrPSc were set at 1,
and all other results were normalized to this value. The PrPSc signal from cells
five passages after inoculation with PrPSc was compared to cells two passages
after inoculation using an independent t test with a cutoff P value of 0.05
(SigmaPlot). Cells were considered positive for PrPSc accumulation if the cor-
rected optical density was greater than 0.18 plus the negative-control value (per
the manufacturer’s instructions). To assay for accumulation of PrPSc over time
and to compare the amount of PrPSc within microgliaSc to the amount in the
original inoculum, the PrPSc signal within late-passage microgliaSc lysates was
compared to early passage microgliaSc lysates and to dilutions of the inoculum,
respectively, using an independent t test with a cutoff P value of 0.05 (SigmaPlot).
MicrogliaC lysates served as the experimental negative controls.
Demonstration of PrPSc infectivity from microgliaSc-derived lysates. Inocula
were derived from mechanical lysates of microgliaSc and microgliaC as described
above for the preparation of inocula from Rov9 cells. Rov9C cells (the target
cells) were then inoculated as described above with three dilutions (1/20, 1/200,
and 1/2,000) of the microgliaSc and microgliaC inocula. The Rov9 cells were then
expanded once and split 1/5 three times. Lysates from the Rov9 cells were
analyzed for PrPSc accumulation in a single HerdChek scrapie antigen test kit
ELISA (IDEXX) plate and reported as the corrected optical density. Cells were
considered positive for PrPSc accumulation if the corrected optical density was
greater than 0.18 plus the negative-control value (per the manufacturer’s instruc-
tions). The PrPSc signal of each of the microgliaSc-exposed Rov9 cells was
compared to the signal of the respective microgliaC-exposed Rov9 cells using an
independent t test with a cutoff P value of 0.05 (SigmaPlot).
Inoculation of immortalized microglia with PrPSc and antibody-based inhibi-
tion. Immortalized microglial cultures were cloned by limiting dilutions in 96-
well, plastic, flat-bottom tissue culture plates. Twenty wells contained small
colonies that were visualized and split 1/2 into replicate 96-well formats. One
replicate was inoculated with 1 l of the Rov9Sc lysate, and the other replicate
was inoculated with 1 l of the Rov9C lysate (negative control) in 100 l of
OMEM. After the cells reached confluence, the cells and medium (with residual
inoculum) were expanded in toto into 24-well plates and cultured in a total
volume of approximately 1 ml of OMEM. One week later, an additional 5 l of
Rov9Sc lysate (Rov9C lysate for negative-control cells) was added to the appro-
priate wells, and 4 days later, 0.5 ml of OMEM was added to each well. When the
cells reached confluence, the cells and medium were first expanded into six-well
tissue culture plates (approximately 3 ml total of OMEM per well) and then
finally into 75-cm2 tissue culture flasks (25 ml total of OMEM), each time
without dilution. Cells were then serially passaged 1/5 at confluence in OMEM
using standard techniques. At select passage points, an aliquot of cells was
collected, lysed, and evaluated for PrPSc accumulation by ELISA as described
above. Cells were considered positive for PrPSc accumulation if the corrected
optical density was greater than 0.18 plus the negative-control value (per the
manufacturer’s instructions) after five 1/5 splits or later. PrPSc was verified by
immunoblotting (see below).
PrPSc accumulation within the PrPSc-positive SV40 large-T-antigen-trans-
formed cell line (B6) was then inhibited by a prion-specific antibody. Similar to
the previously described method, B6 cells were treated for 13 days with the
recombinant anti-prion protein Fab D18 (InPro Biotechnology), which has dem-
onstrated the ability to bind membrane-bound PrPC and inhibit PrPSc accumu-
lation in murine neuroblastoma cells (ScN2a cells) (46). Treated B6 cells were
then split 1/5, without antibody, every 4 days for 4 weeks and then collected for
immunoblot analysis as described below. The recombinant anti-prion protein
Fab R72 (InPro Biotechnology), which does not bind to cell surface PrPC and
thus does not inhibit PrPSc accumulation (46), was used as the negative control.
All antibody inhibition experiments were performed in triplicate.
Immunoblot detection of PrPSc in cell cultures. Since the ELISA does not
utilize the standard method of protease digestion to discriminate between PrPSc
and PrPC, cells were also collected for immunoblot confirmation of protease
resistance. Primary cells were immunoblotted by a method similar to the method
previously described (32). Approximately 2 to 3 million microgliaSc and microg-
liaC were trypsinized into solution and washed with 1 D-PBS. The resulting
pellet was lysed for 1 to 2 h in 1 ml of lysis buffer containing 0.5% (vol/vol)
Nonidet P-40 (Roche) and 0.5% (wt/vol) sodium deoxycholate (Sigma) in 10 mM
Tris buffer (pH 7.4). Aliquots (100 to 250 l) of lysate were brought up to a total
volume of 500 l by using additional lysis buffer. An equal volume of 4% (wt/vol)
N-lauroylsarcosine sodium salt (Sigma) solution in PBS was added to the lysate
and incubated for 15 min at 37°C, followed by DNase I (100 g/ml) (Roche)
treatment for 30 min at 37°C. Samples were centrifuged 1,100  g for 5 min at
room temperature, and 1 ml of the supernatant was treated with proteinase K (50
g/ml) (Roche) for 1 h at 37°C. Replicate samples were incubated for 1 h at 37°C
without proteinase K. Eighty microliters of 4% (wt/vol) phosphotungstic acid in
170 mM MgCl2 was added, the samples were incubated for 1 hour at 37°C, and
following centrifugation at 16,500  g at room temperature, the pellet was
resuspended in 16 l of water. Each sample (16 l) was mixed with 7 l of 4
NuPAGE sample buffer and 2.5 l of 10 reducing agent (Invitrogen) and then
boiled for 10 min. The samples were electrophoresed for 50 min at 200 V using
the NuPAGE precast 12% Bis-Tris-buffered sodium dodecyl sulfate-polyacryl-
amide gel system (Invitrogen) with morpholinepropanesulfonic acid (MOPS)
running buffer. NuPAGE antioxidant (Invitrogen) was added to the inner-cham-
ber running buffer. Gels were electroblotted for 50 min at 300 mA onto a
0.45-m polyvinylidene fluoride (PVDF) (Millipore) membrane, using the semi-
dry Biometra Fastblot B33 apparatus and transfer buffer containing 25 mM Tris
(pH 8.3), 150 mM glycine, and 10% (vol/vol) methanol. Following the transfer,
the PVDF membrane was fixed for 20 seconds in 100% methanol, air dried, and
then immunoblotted or stored dry overnight. PVDF membranes were blocked in
casein blocker (Pierce) with 0.05% (vol/vol) Tween 20 for 1 hour at room
temperature. The prion protein was detected by a 1-hour incubation at room
temperature with the monoclonal antibody F99/97.6.1 (produced in our labora-
tory; also available from VMRD, Inc.) at a concentration of 3.5 g/ml in blocking
buffer. The membrane was then washed three times in TBST (150 mM NaCl and
0.05% Tween 20 in 10 mM Tris [pH 8.0]) and incubated for 30 minutes at room
temperature with a goat anti-mouse IgG1 antibody conjugated to horseradish
peroxidase (catalog no. 1070-05; Southern Biotechnology Associates) and di-
luted 1:5,000 in blocking buffer. Following five additional washes in TBST, the
membrane was incubated with chemiluminescent substrate (Western Lightning;
Perkin Elmer) for 3 min. Signals were visualized by exposing the membrane to
radiographic film (ISC BioExpress) and evaluated for the proper banding pattern
associated with proteinase K-resistant PrPSc.
For detection of PrPSc within the SV40 large-T-antigen-transformed cell line
(B6), the TeSeE Western blot kit (Bio-Rad, France) was used following the
manufacturer’s instructions. Fifteen to 20 microliters of the final sample suspen-
sion was electrophoresed for 60 to 90 min at 250 V using precast 12% Tris-HCl
Ready gels (Bio-Rad) in 25 mM Tris (pH 8.3), 192 mM glycine, and 0.1% sodium
dodecyl sulfate running buffer. Gels were electroblotted for 60 min at 115 V onto
a 0.22-m nitrocellulose membrane (Bio-Rad), using the a Mini-Protean 3 cell
(Bio-Rad) and transfer buffer containing 1 Tris-CAPS [3-(cyclohexylamino)-
1-propanesulfonic acid] (Bio-Rad) and 15% ethanol. Following the transfer, the
nitrocellulose membrane was fixed for 10 s in 100% ethanol and briefly
transferred to distilled water. The immunoblotting procedure for the detec-
tion of the prion protein was similar to the method described above for the
primary microglia, except for the use of reagents, including antibodies, pro-
vided in the TeSeE kit.
Inoculation of PrPSc-accumulating primary microglia with CAEV and evalu-
ation of effect of CAEV on extracellular PrPSc release. At passage 10 after PrPSc
inoculation, primary microgliaSc were plated at a concentration of 1  105/well in
24-well plastic tissue culture plates. MicrogliaC were treated similarly and served as
negative controls for this experiment. The Cork strain of CAEV, in 0.5 ml of total
OMEM, was added to the cells (microgliaSc-CAEV and microgliaC-CAEV) at a con-
centration sufficient to infect the majority of the cells within 7 days (based on a
previous viral infection experiment [data not shown]) as assayed by immunocyto-
chemistry, which is described below. Aliquots of both cell types were also sham
inoculated with medium only (microgliaSc-sham and microgliaC-sham) to serve as
negative controls for the viral inoculation. All inoculations were performed with six
replicates. At days 4, 8, 12, 16, and 19 after virus inoculation, culture supernatants
were collected and saved at 80°C for analysis by HerdChek scrapie antigen test kit
ELISA (see above) and for transmission studies (see below). A standard curve
prepared from diluted Rov9Sc inoculum (1/50, 1/100, 1/400, 1/800, and 1/1,600) was
used to normalize corrected optical density results between ELISA plates. The PrPSc
signal of microgliaSc-CAEV supernatants was compared to the PrPSc signal of microg-
liaSc-sham supernatants using an independent t test with a cutoff P value of 0.05
(SigmaPlot).
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Demonstration of PrPSc infectivity from microgliaSc-CAEV-derived superna-
tants and evaluation of effect of CAEV on intracellular PrPSc accumulation.
Primary microgliaC at passage 21 were plated in 24-well plates at 2  105 cells per
well. One day later, 400 l of the cell culture supernatant on day 4 after viral
inoculation (see previous paragraph) was applied to the cells, in triplicate for
each of the four treatment groups (microgliaSc-CAEV, microgliaSc-sham, microg-
liaC-CAEV, and microgliaC-sham). Once the cells reached confluence, they were
expanded sequentially into 12-well plates and into 25-cm2 flasks. At day 26
postinoculation, aliquots of microglial cells were plated into chambered slides to
confirm that the cells were infected with CAEV (see below), and four-fifths of
the total cells were collected and lysed (as described above) for analysis by
HerdChek scrapie antigen test kit ELISA. A standard curve prepared from
diluted Rov9Sc inoculum (1/100, 1/400, 1/800, and 1/1,600) was used to normalize
corrected optical density results. The PrPSc signal of microgliaSc-CAEV lysates was
compared to the PrPSc signal of microgliaSc-Sham lysates using an independent t
test with a cutoff P value of 0.05 (SigmaPlot).
Immunocytochemical detection of CAEV in primary microglia. Cells were
fixed with 4% buffered zinc formaldehyde (Z-fix; Anatech Ltd.) for 2 min and
then rinsed in 70% ethanol. CAEV antigen was detected using the MAb 10A1
(VMRD, Inc.) directed against 28-kDa capsid protein. Negative controls in-
cluded the use of isotype-matched antibodies raised against an irrelevant antigen,
omission of the primary antibody, and omission of both the primary and second-
ary antibodies. CAEV-infected goat synovial membrane cells, derived from neo-
natal goats (29), served as positive controls for the immunocytochemistry.
RESULTS
Establishment and characterization of primary and trans-
formed fetal sheep brain cells. To study the cellular and mo-
lecular changes associated with prion conversion in a natural
host-TSE system, primary brain cell cultures were derived from
a Suffolk cross domestic sheep fetus that was homozygous for
the prnp VRQ allele (Val-136, Arg-154, and Gln-171). Primary
cell cultures were adherent and viable for approximately 20
passages. Additionally, a cell line derived from the primary
brain cells was created by transformation with a plasmid con-
taining the SV40 virus large T antigen. Increased rate of
growth, lack of contact inhibition, and immunoreactivity for
the large T antigen confirmed transformation of the cell cul-
ture (data not shown). The transformed cell line has demon-
strated viability for 60 passages, as of this writing, and shown
no evidence of cell pathology. Both the primary brain cultures
and the transformed cell line demonstrated expression of sev-
eral microglial markers by both immunocytochemistry and flow
cytometry (Table 1), although the primary microglia cultures
lacked CD68 expression. By immunocytochemistry, approxi-
mately 90% of cells demonstrated immunoreactivity for the
given markers (data not shown). The approximately 10% of
cells lacking immunoreactivity were morphologically indistin-
guishable from those cells that were demonstrating immuno-
reactivity. On the basis of the phenotypic features, we classified
both the primary cell cultures and the transformed cell line as
sheep microglia.
PrPSc infection of primary microglia. To determine the per-
missiveness of cultured sheep microglia to PrPSc infectivity,
primary microglia were exposed to the prnp genotype-matched
Rov9Sc-derived PrPSc. Lysates of the inoculated microglia (mi-
crogliaSc) were collected at several time points, and commer-
cially available ELISAs were used to screen the lysates for
PrPSc. Primary microgliaSc demonstrated accumulation of
PrPSc over time, as illustrated by an increasing PrPSc signal in
cell lysates, even after dilution of the cells and residual inoc-
ulum due to several 1/5 splits (Fig. 1A). The cell growth rate or
morphology of microgliaSc and microgliaC were not different
from each other, which is consistent with previously reported
findings (11).
To determine the relative level of PrPSc accumulation com-
pared to the original inoculum and to further verify the detec-
tion of newly converted PrPSc versus detection of residual
inoculum, the amount of PrPSc in a lysate of microglial cells at
passage 9 (representing two expansions and seven 1/5 splits)
was compared to the amount of PrPSc in the inoculum. The
inoculum was tested at its original concentration and at a 57
(1/78,125) dilution, representing the seven 1/5 splits (and two
expansions) of the microgliaSc cells at passage 9. The level of
PrPSc in the 1/57-diluted inoculum was below the detection
limit of the ELISA, as evidenced by results similar to those for
uninoculated microglia cells. The microgliaSc lysates from pas-
sage 9 demonstrated a significantly higher PrPSc signal than the
1/57-diluted inoculum did (representing the expected PrPSc
signal after seven splits if no accumulation was occurring in the
microgliaSc) (Fig. 1B). If the cells lacked the ability to form
nascent PrPSc, then the expected result would be that the
passage 9 sample would be equal to the 1/57-diluted inoculum.
As this was not seen, it was concluded that de novo conversion
and accumulation of PrPSc were occurring within the primary
sheep microglia in order to compensate for the dilution of
PrPSc that occurs during splitting of cells during routine cell
culture.
The ELISA that was utilized in this study uses a proprietary
chemical, which preferentially binds beta-sheets, to distinguish
PrPSc from PrPC. Therefore, immunoblotting of microglial ly-
sates was used to confirm proteinase K resistance, which is the
gold standard for PrPSc detection, of the microglia-derived
PrPSc and to compare the glycoform profile compared to the
profile of Rov9Sc-based inoculum. MicrogliaSc accumulated
proteinase K-resistant PrPSc that migrated with a profile dif-
ferent from that of scrapie-positive brain material (Fig. 2A),
but with a profile similar to that of the Rov9Sc-based inoculum
(Fig. 2B).
The infectivity of the intracellular PrPSc produced by the
microglia was analyzed by exposing Rov9C cells to three dilu-
tions (1/20, 1/200, and 1/2,000) of microglial cell lysates. The
Rov9C cells inoculated with microgliaSc lysates demonstrated
accumulation of PrPSc over time as evidenced by an increasing
ELISA optical density at each subsequent time point (Fig. 3).
Additionally, Rov9C cells exposed to higher concentrations of
microgliaSc inoculum demonstrated higher levels of PrPSc ac-
cumulation (Fig. 3). The dose responsiveness of the microglia-
derived PrPSc is consistent with infectivity.
TABLE 1. Phenotypes of primary sheep brain cultures and
transformed glial cell line
Cells Method
Markera
RCA-I CD14 CD68 Nonspecificesterase
Primary Immunocytochemistry    
Flow cytometry    NA
Transformed Immunocytochemistry    
Flow cytometry    NA
a The presence () or absence () of markers is shown. The markers are
Ricinus communis agglutinin-1 (RCA-I), CD14 (catalog no. MM61A; VMRD,
Inc.), CD68 (EBM11; Dako), and nonspecific esterase. NA, not applicable.
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PrPSc infection of transformed microglia and inhibition of
PrPSc accumulation. Transformed microglial cells were cloned
and inoculated to test whether sheep microglial cell cultures
with a longer culture life span than the primary sheep microg-
lial cell culture support PrPSc accumulation. Clones were in-
oculated with Rov9-derived PrPSc and then screened by
ELISA for evidence of PrPSc accumulation. Twenty clones
were inoculated, and 15 of those clones were stable and were
able to be expanded and tested for PrPSc accumulation. One of
the 15 clones tested positive for PrPSc by ELISA at passage five
and later (data not shown). The positive clone, B6, was the
clone that was the slowest to grow to confluence during the
initial inoculation period, taking 16 days compared to an av-
erage of 6 days for the 14 negative clones. The PrPSc signal in
the transformed cell line remained consistently low, compared
to the signal in the primary sheep microglia, and spontaneous
loss of PrPSc was seen after approximately 15 passages.
To further characterize the PrPSc being accumulated within
the transformed microglia, the positive clone was treated with
the recombinant anti-prion Fab D18. Following a 13-day ex-
posure to this Fab and 4 weeks of culture without the Fab, the
transformed microglial cell line demonstrated loss of PrPSc
detectable by ELISA (data not shown) and detectable by im-
munoblotting compared to the cultures treated with the neg-
ative-control recombinant anti-prion Fab R72, which main-
tained detectable levels of PrPSc (Fig. 4). This specific
antibody-based inhibition of PrPSc accumulation and the mul-
tiple assays used to detect PrPSc increase over time indicate
FIG. 1. PrPSc accumulation in primary microglia. Primary sheep
microglia were inoculated in triplicate with either PrPSc-containing
(microgliaSc) or PrPSc-lacking (microgliaC) cell lysates derived from
the PrPSc-positive or -negative Rov9 cell line (60), respectively, and
then serially passaged. Lysates of microgliaSc were assayed for PrPSc by
commercial ELISA, and the corrected optical density was determined.
The equation for the corrected optical density is OD450  OD620
(OD450 being the optical density at 450 nm) per the manufacturer’s
instructions. (A) ELISA results comparing the level of PrPSc in late-
passage (five passages after PrPSc inoculation [P-5]) microgliaSc versus
early passage (P-2) microgliaSc. Data were normalized using a standard
curve. MicrogliaSc results were set at 1, and all other results were
normalized to this value (y axis). Each value represents the mean  1
standard deviation (error bar). Results for microgliaSc at P-5 and P-2
were compared by a statistical analysis, and the microgliaSc values at
P-5 and P-2 were significantly different (P  0.005) as indicated by an
asterisk. (B) ELISA results comparing the relative level of PrPSc in
late-passage (P-9) primary microgliaSc to the original inoculum. Data
were normalized to the ELISA plate positive control (y axis) to account
for plate-to-plate variation between testing repeats performed at dif-
ferent times. Results for microgliaSc at passage 9 were compared to the
values for microgliaC and both Rov9Sc-based inoculum data points.
The values for P-9 microgliaSc were significantly different (P  0.05)
from those for microgliaC and the diluted RovSc data points, as indi-
cated by an asterisk. neg. control, negative control.
FIG. 2. Immunoblot analysis of primary sheep microglia following
exposure to PrPSc (microgliaSc) and unexposed microglia (microgliaC).
Microglia were lysed, treated with proteinase K (PK) () or not
treated with proteinase K (), precipitated with phosphotungstic acid,
and immunoblotted using the monoclonal anti-PrP antibody
F99.97.6.1. (A) Comparison of prion immunoreactivity from sheep
brain, microgliaSc, and microgliaC. (B) Comparison of proteinase K-
resistant glycoform patterns between Rov9Sc and microgliaSc. The po-
sitions of molecular mass standards (in kilodaltons) are indicated to
the left of the immunoblots.
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that the PrPSc detected in the microglial cells represents PrPSc
molecules that are newly formed in microglia.
Enhancement of PrPSc levels by CAEV coinfection. Previous
studies with ScN2a cells and MLV, a gammaretrovirus, have
demonstrated enhancement of prion infectivity release into the
culture supernatant (39). While no gammaretroviruses of small
ruminants have been identified (17), sheep and goats are sus-
ceptible to the SRLVs VISNA and CAEV, which are closely
related to one another and are considered members of the
same lentivirus group (45). While gammaretroviruses and len-
tiviruses have unique properties, much of the basic biology
between these two groups of retroviruses is shared. To deter-
mine whether SRLV coinfection enhances the release of PrPSc
into the culture supernatant, similar to the results of MLV in
ScN2a cells, late-passage primary microgliaSc and microgliaC
were inoculated with the Cork strain of CAEV. CAEV-Cork
induced less cytotoxicity than the other tested SRLV strains
(VISNA 84-28, VISNA LMH11, and VISNA WLC-1) that
each resulted in nearly 100% cell lysis within 1 week (data not
shown). The culture supernatants were collected regularly and
assayed for relative levels of PrPSc concentration by normal-
ized ELISA optical densities. There was no detectable differ-
ence between cultures infected and uninfected with SRLV in
cell growth, as determined by rate to confluence, or phenotype.
The results demonstrate that following subsequent infection by
CAEV, microglia cells that were already PrPSc infected have
significantly enhanced (up to 1.5-fold) PrPSc release into the
culture supernatant compared to that of microgliaSc-Sham (Fig.
5A). The supernatants from cultures of microgliaC-CAEV and
microgliaC-Sham remained free from detectable levels of PrPSc,
indicating that CAEV does not result in detectable levels of
spontaneous conversion of PrPC into PrPSc.
It is known that the mechanism of PrPSc transmission within
one cell culture system may vary compared to another cell culture
system. For instance, in ScN2a cells, the spread of PrPSc is mainly
vertical (i.e., from mother to daughter cells) (22), whereas spread
within Rov9 cells is horizontal to nearby cells, with rare spreading
to spatially distant cells (44). To determine whether supernatant-
derived PrPSc, which was enhanced by SRLV coinfection in pri-
mary sheep microglia, is associated with infectivity toward pri-
mary microglia, microgliaC were inoculated with supernatants
from the previous primary microglia experiment that contained
both PrPSc and CAEV. Additionally, this experiment also served
three additional purposes: to repeat the observed enhancement of
PrPSc accumulation following CAEV coinfection, to determine
whether the increase in PrPSc also applied to intracellular PrPSc,
and to determine whether simultaneous PrPSc-CAEV coinfection
(versus CAEV infection of established PrPSc-infected microglia
as shown above) yielded a similar enhancement of relative PrPSc
levels. Lysates were analyzed by ELISA to determine the relative
amounts of PrPSc. Both microgliaSc-CAEV and microgliaSc-Sham
contain detectable levels of PrPSc, thus confirming that primary
microgliaSc-derived PrPSc is infectious to microglia and sug-
gesting that horizontal spread within microglial cultures is likely
(Fig. 5b). Additionally, microgliaSc-CAEV lysates demonstrated
an approximately twofold-higher PrPSc signal compared to the
signal of microgliaSc-Sham (Fig. 5b). Thus, these results confirm
the repeatability of CAEV-induced enhancement of PrPSc ac-
cumulation in microglia, show that the intracellular PrPSc lev-
els are also elevated, and demonstrate that the PrPSc enhance-
ment is evident with simultaneous PrPSc and CAEV
coinfections. These two coinfection experiments (Fig. 5) indi-
cate an overall increase, up to twofold, in PrPSc within primary
sheep microglia that are coinfected with CAEV. As expected,
FIG. 3. Transmission of microglia-derived PrPSc to Rov9C cells.
Rov9C cells were inoculated in triplicate with three dilutions of microg-
liaSc lysates. The inoculated Rov9 cells were serially passaged, lysed,
and analyzed for PrPSc levels by ELISAs. Results for each group of
inoculated cells at passage 4 were compared to the results for the
corresponding mock-inoculated cells, and the values for inoculated
cells at passage 4 that were statistically different (P  0.05) from the
value for the corresponding mock-inoculated cells are indicated by an
asterisk. All samples were run on the same ELISA plate; thus, results
are reported as the corrected optical density (y axis). Each value
represents the mean  1 standard deviation (error bar) of the sample
corrected optical density. The equation for the corrected optical den-
sity is OD450  OD620 (OD450 being the optical density at 450 nm) per
the manufacturer’s instructions. Inoc, inoculated; Mock, mock inocu-
lated.
FIG. 4. Immunoblot analysis of PrPSc-infected sheep microglial cell
line after incubation with the recombinant anti-prion Fab D18. Pri-
mary sheep cultures were transformed with the SV40 virus large T
antigen, cloned by limiting dilutions, and then inoculated with PrPSc.
The clone that was positive for PrPSc was incubated with Fab D18 for
13 days and then cultured in the absence of the Fab for 4 weeks. Cells
were lysed, treated with proteinase K (PK) () or not treated with
proteinase K (), and immunoblotted using the TeSeE Western blot
kit (Bio-Rad, France). Lysates of replicate PrPSc-infected B6 cells that
were treated with the control anti-prion Fab R72, which does not
inhibit PrPSc accumulation, are included as a control for spontaneous
loss of detectable PrPSc. The positions of molecular mass standards (in
kilodaltons) are indicated to the left of the immunoblot.
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primary microglia not infected with PrPSc (microgliaC-CAEV
and microgliaC-Sham treatment groups) did not demonstrate
detectable levels of PrPSc. CAEV infection was verified by
immunocytochemistry for the CAEV 28-kDa capsid protein
(data not shown).
DISCUSSION
Scrapie is an important disease in the United States and has
been targeted for eradication (47). While scrapie has been
recognized since the early 18th century (48), many questions
still remain including the details of transmission between ani-
mals and the identification of factors that promote transmis-
sion and infection. Recent studies in mice and mouse-derived
cell cultures have shown that gammaretroviral infections en-
hance the amount of prion infectivity produced by prion-in-
fected cells (39). Our results have extended this connection to
sheep-derived microglia cultures coinfected with an SRLV.
While the VISNA strains that were most readily available were
too cytopathic for these studies, we have shown that coinfec-
tion with the very closely related SRLV CAEV-Cork strain
results in increased PrPSc accumulation in sheep brain macro-
phages (microglia), as evidenced by the increase in PrPSc signal
both within the supernatant and within the microglial cells.
Additionally, we have demonstrated that the enhancement of
PrPSc accumulation occurs following either sequential PrPSc/
CAEV infection or simultaneous coinfection and that both the
intracellular microglia-derived PrPSc and extracellular microg-
lia-derived PrPSc are infectious.
Studies analyzing prion and retroviral coinfections in natural
hosts are limited. A previous report has demonstrated PrPSc in
macrophages within lesions of SRLV-induced lymphofollicular
mastitis in sheep (41). However, the mechanism of colocaliza-
tion was not determined. One possible mechanism is recruit-
ment of macrophages and follicular dendritic cells, unrelated
to prion pathogenesis, to tissues with SRLV-induced inflam-
mation, which then increased the number of PrPSc-permissive
cells in the mammary gland. A second possible mechanism is
that the SRLV infection specifically enhances PrPSc accumu-
lation in the macrophages and follicular dendritic cells. While
these two mechanisms are not mutually exclusive, our results
demonstrating SRLV-induced enhancement of PrPSc in microg-
lia (brain-derived macrophages) suggest that a specific inter-
action may be at least partially responsible for the presence of
PrPSc in SLRV-induced mastitis.
The SLRV-induced enhancement of PrPSc in these microg-
lia cultures is modest; thus, the in vivo relevance of any direct
interaction between SRLV and PrPSc is not known. However,
prion diseases are extremely chronic diseases that take months
to years to fully develop (61); thus, small changes in the rate of
PrPSc accumulation can potentially be significant following am-
plification over that extended time period. Furthermore, both
PrPSc and SRLV are present independently in the same cell
types, e.g., macrophages (20, 23, 24, 43, 49), dendritic cells (24,
31, 53), and microglia (5, 7, 16, 33). Additionally, nearly one in
four domestic sheep within the United States is infected with
VISNA (56). Thus, given the increased PrPSc accumulation
associated with SRLV coinfection that is reported herein, the
overlapping cellular tropism of PrPSc and SRLVs, and the
prevalence of SRLV, it is important to determine the extent of
interaction between these two agents in vivo and the effects, if
any, on any scrapie eradication measures.
This study does not investigate the mechanism of interaction
between SRLVs and PrPSc. Possible mechanisms for the en-
hanced PrPSc accumulation in the sheep microglia include but
are not limited to the coinfecting SRLV increasing PrPC pro-
tein expression, enhancing access to conversion accessory mol-
ecules, increasing colocalization of PrPC and PrPSc during viral
assembly, and increasing transmission of PrPSc by cotransmis-
sion with the virus. The study using MLV and ScN2a cells
demonstrated that PrPC and PrPSc are recruited to virions (39),
FIG. 5. Effects of CAEV coinfection on PrPSc accumulation in pri-
mary sheep microglia and transmission of microglia-derived PrPSc to
primary microglial cells. (A) PrPSc accumulation in the culture super-
natant of primary microglia infected with CAEV after establishment of
PrPSc accumulation. MicrogliaSc and microgliaC were inoculated with
CAEV, and cell culture supernatants were collected at 4, 8, 12, 16, and
19 days after CAEV inoculation (dpi). Aliquots of supernatant were
analyzed by an ELISA for PrPSc levels, which were normalized via a
standard curve. Normalized 4 dpi microgliaSc-CAEV levels were set at 1,
and all other results were normalized based on this value (y axis). Six
replicates for each treatment group were used. At each time point,
results for microgliaSc-CAEV were compared to the results for microg-
liaSc-Sham in a statistical analysis; microgliaSc-CAEV values that were
significantly different from microgliaSc-Sham values are indicated as
follows: , P  0.05; †, P  0.0005. (B) PrPSc levels in the lysates of
primary microglia simultaneously coinfected with PrPSc and CAEV.
MicrogliaC were inoculated with the 4 dpi culture supernatants from
the previous experiment: Sc-CAEV, Sc-Sham, C-CAEV, and C-Sham.
At 26 dpi, cell lysates were analyzed by an ELISA for PrPSc levels,
which were normalized via a standard curve. Normalized microgliaSc-Sham
levels were set at 1, and all other results were normalized to this value
(y axis). Three replicates for each treatment group were used. Results
for microgliaSc-CAEV were compared to the results for microgliaSc-Sham
and evaluated statistically; the microgliaSc-CAEV value that was signif-
icantly different (P  0.01) from the microgliaSc-Sham value is indicated
by an asterisk. Each error bar represents 1 standard deviation.
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suggesting that increased PrPSc transmission is likely to play at
least some role in the enhancement of PrPSc accumulation.
Another recent study investigated the interaction of PrPSc and
minute virus of mice, a parvovirus, and demonstrated that the
parvovirus-infected cells internalize exogenous PrPSc more ef-
ficiently than the virus-free cells, most likely due to virus-
induced changes in the cellular membranes (4). However, it
remains to be determined whether similar mechanisms are
induced by infections with retroviruses and other viruses. An-
other possible mechanism for the enhanced prion accumula-
tion is that there are virus-induced changes in the abundance
and/or character of RNA, which has been suggested as a pos-
sible cofactor for the conversion of PrPC to PrPSc (2, 15, 19,
21). Determining the mechanism(s) of the virus-induced en-
hancement of PrPSc accumulation warrants further study,
which may also help to elucidate some of the basic cellular
mechanisms of PrPSc conversion.
During the course of scrapie infection, numerous cell types,
including glia, macrophages, and follicular dendritic cells,
demonstrate accumulation of PrPSc (58), but the cell-specific
mechanisms that allow for prion conversion are not known.
The ability to investigate these mechanisms requires the tools
to study PrPSc infection in these various cell types, mainly
having permissive cell culture systems from a variety of cell
types. Herein we describe the second cell line derived from a
natural TSE host and the first microglial cell culture derived
from a natural TSE host (59).
These microglial cells are of the highly susceptible VRQ
genotype (Val-136, Arg-154, and Gln-171). Acquiring PrPSc-
containing VRQ/VRQ sheep brain for research material can
be difficult in the United States due to the rarity (approxi-
mately 0.5%) of this genotype in the United States (57). While
it is recognized that this study used an inoculum derived from
lagomorph cells, it should be noted that the inoculum’s PrPSc
has an ovine, and not lagomorph, amino acid sequence (prnp in
Rov cells is the ovine insert). Thus, the disadvantage of utiliz-
ing material derived from a leporine source is outweighed in
this particular case by the availability of Rov9-derived PrPSc
and its matched ovine amino acid sequence. Furthermore, now
that the concept of PrPSc-susceptible sheep microglia cultures
has been demonstrated, these cells can be utilized in further
studies to determine the relevance of prion allelic usage, prion
allelic susceptibility, and other sheep-specific prion questions.
Cell culture models of PrPSc accumulation have been used
for numerous studies to screen for inhibitors of PrPSc accumu-
lation (59). However, recent work has indicated one of the
pitfalls of using cell culture models, namely, that the amount of
PrPSc accumulating in cells is inversely related to the mitotic
rate of the cell cultures (22). Thus, the ability to cure cell
culture systems of PrPSc differs significantly compared to mi-
totically inactive neurons, which are infected with PrPSc in
clinical patients. Our results support this conclusion, as the
only positive cell line derived from the transformed microglia
was the clone that was slow growing during the initial inocu-
lation phase and even this clone lost the ability to maintain
detectable levels of PrPSc after the cultures began achieving
confluence at a faster rate. While the mitotic activity of cell
culture systems may alter the biological relevance of using
these systems to screen for antiprion compounds, cell culture
systems do have the ability to screen for factors that promote
PrPSc accumulation. Multiple lines of evidence suggest a role
for an accessory molecule(s) to enable PrPSc accumulation (35,
54, 55). The coinfection model of PrPSc and SRLV in primary
sheep microglia is one example of using cell cultures to identify
factors that enhance PrPSc accumulation. Further studies, in-
cluding screening for additional factors that promote PrPSc
accumulation in microglia and studying those cofactors in a
variety of PrPSc-permissive cell lines, are warranted.
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